A bill to direct the Food and Drug Administration to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs from the People's Republic of China or other foreign countries, to establish enhanced safeguards for imported drug products, and for other purposes.

Based on the bill's title, this legislation would direct the FDA to prevent importation of counterfeit, unapproved, misbranded, or adulterated drugs from China and other foreign countries, and establish enhanced safeguards for imported drug products. The bill aims to strengthen FDA oversight of the drug supply chain at the border. The full text was not available for review.

Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.